Nick's Commute Briefings | Podcast on RSS.com

Nick's Commute Briefings

Nick's Commute Briefings

by Nick Warth

Self-Improvement

OZU Briefing

EU CHB Discussions pre EASL26

EU CHB Discussions pre EASL26

EASL 05 Efimosfermin

EASL 05 Efimosfermin Brief

EASL 04 Congress

EASL 04 Congress Brief

EASL 03 Guidelines Update

EASL 03 Guidelines Update

EASL 02 B-Well

EASL 02 B-Well brief

EASL 01 B-Sure

EASL 01 B-Sure summary

Mini MBA 10 - Pharma Finance for Commercial People

Focuses on core financial concepts within the pharmaceutical industry, emphasizing their application for strategic decision-making and effective collaboration between commercial and finance teams. Key topics include Net Present Value (NPV) and Risk-Adjusted Net Present Value (rNPV) for evaluating drug candidates, Internal Rate of Return (IRR) for assessing investment profitability, and the Weighted Average Cost of Capital (WACC). The texts also explain Discounted Cash Flow (DCF) analysis for valuation, methods for building robust business cases for pipeline assets, and strategies for translating commercial insights into financial language to foster better partnership. Overall, the documents aim to enhance financial literacy for commercial professionals to improve resource allocation and portfolio optimization in the high-risk pharmaceutical sector.

Mini MBA 09 - Clinical Trial Strategy

Emphasizes the critical need for integrating clinical development and commercial strategy within the pharmaceutical industry. They explain how a holistic approach, starting from the earliest stages of drug development, is essential for optimizing resource allocation, achieving regulatory approval, and ensuring market success. The texts highlight the importance of tools like the Target Product Profile (TPP) and strategic trial design to define value and competitive advantage. Furthermore, they discuss the benefits of pathways like 505(b)(2) for accelerated development and address the challenges of cultural differences between clinical and commercial teams, advocating for stronger collaboration to create a unified, market-driven development plan. Ultimately, these sources argue that early evidence generation and cross-functional alignment are crucial for navigating the complex pharmaceutical landscape and delivering value to both patients and shareholders. 1 source

Mini MBA 08 - Reg Affairs for Commercial People in Pharma

Offers a comprehensive overview of regulatory affairs within the pharmaceutical industry, explaining its critical role in drug development, approval, and commercialization. It details the standard and expedited pathways for drug approval by major global regulatory bodies like the FDA and EMA, highlighting how these accelerated programs can reduce time to market. The text also explores the concept of regulatory reliance as an efficiency tool and emphasizes the impact of regulatory timelines on commercial readiness. Finally, it underscores the importance of a strategic regulatory approach and cross-functional collaboration, along with international harmonization efforts to streamline global processes and ensure product safety and efficacy.

1 of 5